Generics Bulletin is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Claims Lead Among Adalimumab Biosimilars In Europe

Executive Summary

With quarterly sales up to $36m, Biogen says its Imraldi rival to Humira is the market-leading adalimumab biosimilar in Europe.

Related Content

Biogen’s Henshaw Insists Data Is Key In Bolstering Biosimilars
Kabi Introduces Idacio Into Crowded German Adalimumab Market
Samsung Bioepis’ Etanercept Nod Prompts US Lawsuit
Fresenius Nod In EU Adds To Crowded Adalimumab Market
Benepali Surge And Imraldi Gains Drive Biogen Biosimilars Past US$500m
German funds select Imraldi due to price
Imraldi sets pace on German price cuts





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts